☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
GSK
GSK Highlights the P-III (RUBY) Trial Results of Jemperli to Treat Endometrial Cancer at Society of Gynecologic Oncology 2024
March 18, 2024
GSK Reports P-III (DREAMM-8) Study Results of Blenrep for Treating Relapsed/Refractory Multiple Myeloma (RRMM)
March 7, 2024
GSK Reports Results from the P-III (EAGLE-1) Study of Gepotidacin for the Treatment of Urogenital Gonorrhoea (GC)
February 26, 2024
GSK’s Bepirovirsen Receives the US FDA’s Fast Track Designation for the Treatment of Hepatitis B
February 13, 2024
GSK Reports the P-III Results for Blenrep (belantamab mafodotin) in Combiantion with BorDex (dexamethasone) to Treat Multiple Myel...
February 7, 2024
GSK Reports sBLA Acceptance of Arexvy Under Priority Review by the US FDA for Preventing RSV Disease
February 6, 2024
Load more...
Back to Home